Share on StockTwits

Alexion Pharmaceuticals (NASDAQ:ALXN) is scheduled to announce its earnings results on Thursday, January 30th. Investors that wish to listen to the company’s conference call can do so using this link.

Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 133.01 on Wednesday. Alexion Pharmaceuticals has a 1-year low of $81.82 and a 1-year high of $142.98. The stock’s 50-day moving average is $131.9 and its 200-day moving average is $118.5. The company has a market cap of $26.080 billion and a P/E ratio of 73.43.

Several analysts have recently commented on the stock. Analysts at Barclays reiterated an “overweight” rating on shares of Alexion Pharmaceuticals in a research note to investors on Friday, January 10th. They now have a $141.00 price target on the stock, up previously from $127.00. On a related note, analysts at Nomura initiated coverage on shares of Alexion Pharmaceuticals in a research note to investors on Wednesday, January 8th. They set a “buy” rating and a $150.00 price target on the stock. Finally, analysts at UBS AG raised their price target on shares of Alexion Pharmaceuticals from $130.00 to $150.00 in a research note to investors on Monday, January 6th. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $130.59.

In other Alexion Pharmaceuticals news, CEO Leonard Bell unloaded 156,436 shares of the stock on the open market in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $140.80, for a total transaction of $22,026,188.80. Following the transaction, the chief executive officer now directly owns 977,726 shares of the company’s stock, valued at approximately $137,663,821. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.